Under the deal, Peptris Technologies is licensing PEPR124 (RT001), a preclinical-stage drug, to Revio Therapeutics for ...
Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease----Data Presented at the 2025 Muscular ...
A man with a dentist phobia so severe he allowed most of his teeth to "crumble away" has discovered that the bones in his ...
Having found that in biomedical research, the Bird Rock resident and scientist at La Jolla’s Sanford Burnham Prebys has ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
The impact of Illinois Gov. JB Pritzker’s plan to eliminate a health insurance program for noncitizen immigrants ages 42 to ...
The Minnesota Department of Health tests for over 60 different disorders during a newborn screening, and now, two more ...
The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...
A man with a dentist phobia so severe he allowed most of his teeth to “crumble away” has now sought treatment abroad as he ...
Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference: Basel Tuesday, March 18, 2025, 11:00 Hrs [IST] ...
BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback